12:00 AM
 | 
Dec 04, 2000
 |  BC Week In Review  |  Company News  |  Deals

Abgenix, CuraGen, Immunex deal

CRGN and ABGX raised the number of antibodies they will co-develop under a 1999 deal to 250 from 120 (see BioCentury, Dec. 13, 1999). Using CRGN's functional genomics technology, the companies will seek targets related to...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >